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Abstract:
This paper summarizes a series of electrophysiological studies aimed at finding the effects of the activation of 5-HT7 receptors on neu-
ronal excitability as well as on excitatory and inhibitory synaptic transmission in the hippocampus and in the frontal cortex of the rat.
These studies demonstrated that 5-HT7 receptors play an important role in the modulation of the activity of the hippocampal network by
regulating the excitability of pyramidal cells of the CA1 area, as well as via their effect on GABA and glutamatergic transmission. The
reactivity of 5-HT7 receptors in the hippocampus is decreased by repeated administration of antidepressant drugs and increased by
a prolonged high level of corticosterone. More importantly, administration of antidepressant drug, imipramine, prevents the occurrence
of corticosterone-induced changes in the function of hippocampal 5-HT7 receptors. It has also been found that the blockade of 5-HT7
receptors by the selective antagonist SB 269970, lasting for a few days, causes similar changes to those observed after long-term ad-
ministration of antidepressants. Thus, it seems that the pharmacological blockade of 5-HT7 receptors produces faster effects compared
to classic antidepressant drugs. A similarity between the changes in the glutamatergic transmission induced by the blockade of 5 HT7
receptors and those caused by repeated administration of the antidepressant drug, imipramine, has also been found in the frontal cortex.
It has also been shown that the changes in glutamatergic transmission and the impairment of long-term synaptic plasticity in the frontal
cortex of animals subjected to repeated restraint stress are reversed by the blockade of 5-HT7 receptors.
Overall, these studies, together with the data provided by other investigators, support the hypothesis that 5-HT7 receptor antagonists
may become a prototype of a new class of antidepressant drugs. Such compounds will not function by blocking 5-HT reuptake, as many
of the currently used drugs, but through a direct interaction with the 5-HT7 receptor. This type of action is highly selective and usually
does not require the occurrence of adaptive changes in neuronal functions, thus allowing for a much quicker therapeutic effect.
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Introduction
Serotonin (5-hydroxytryptamine, 5-HT) is involved in
a variety of physiological and cognitive processes in-
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cluding sleep, sensory perception, motor activity, tem-
perature regulation, appetite, hormone secretion, no-
ciception and sexual behavior [40]. In the central
nervous system (CNS), serotonin activates numerous
5-HT receptors which have been classified as belong-
ing to seven families and 15 subtypes, on the basis of
their pharmacological properties, coupling to intracel-
lular signaling cascades and protein structure [38].
With the exception of the 5-HT3 receptor, being
a ligand-gated ion channel, the remaining ones belong
to the class of G-protein coupled metabotropic recep-
tors. However, their diversity, interactions with other
neurotransmitter systems and the fact that some 5-HT
receptors subtypes do not yet have a complete func-
tional, biochemical and physiological characteristics,
make it difficult to obtain a full description of the
functionsand roles played by 5-HT in the CNS.
Although the last of the serotonin receptor sub-
types, the 5-HT7 receptor, was identified already al-
most two decades ago [6, 81, 82], the knowledge of
the effects of its activation and functions in the CNS
is not yet fully developed. The 5-HT7 receptor has
been implicated in mood regulation, circadian rhyth-
micity and sleep, the disturbances of which are evi-
dent in the course of depressive disorders [36, 88].
Moreover, some antidepressants exhibit a high affin-
ity for this receptor [1, 52]. Since there are reasons to
believe that it may be involved in the etiology of men-
tal illnesses, this receptor is presently considered one
of the most attractive research targets in this regard
[34, 60, 61].
Early research of the functions of 5-HT7 receptors
concentrated on neurons of the hypothalamic supra-
chiasmatic nuclei (SCN), comprising the “biological
clock” in the mammalian brain. In vitro [37, 53, 85,
104, 105] as well as in vivo [4, 22] animal studies,
conducted using nonselective 5-HT7 receptor ago-
nists, demonstrated that their effects such as phase
shifting of circadian rhythms, inhibition of spontane-
ous activity and inhibition of the light stimulation,
were diminished by the selective 5-HT7 receptor an-
tagonists SB 269970 and DR 4004. Moreover, down-
regulation of the 5-HT7 receptor has been found to oc-
cur in rat SCN after chronic treatment with tricyclic
antidepressants and the SSRI fluoxetine [63, 84]. The
implication of the 5-HT7 receptor in circadian rhythm
phase resetting and the involvement of 5-HT7
receptor-selective antagonists in altering rapid eye
movement (REM) sleep parameters in an opposite
pattern to that observed in human patients with clini-
cal depression, was confirmed in the study conducted
on 5-HT7 receptor knockout mice [35, 60, 89].
Antidepressant drugs currently used in psychiatry
are effective only in part of patients and do not always
produce a complete cure. A successful therapy re-
quires prolonged administration of the drug, which
often causes a number of onerous (and sometimes
hazardous to health) side-effects [46]. Therefore, an
extensive search for new, more effective and safe anti-
depressant drugs is still to be carried out. Two re-
search groups have shown an antidepressant-like ac-
tion of the 5-HT7 receptor antagonist SB 269970 in
animal models of depression: the forced swim and tail
suspension tests [35, 101]. Interestingly, the data sug-
gest that the 5-HT7 receptor antagonist, SB 269970,
raises the level of 5-HT in brain structures thought to
be involved in the pathophysiology of depression i.e.,
hippocampus, frontal cortex and dorsal raphe nuclei
(DRN) [101], but the mechanism of this effect is un-
clear, since 5-HT7 receptors are expressed both in the
DRN as well as in brain structures which receive the
serotonergic innervation [33, 56, 80]. Generally, the
available data indicate that activation of 5-HT7 recep-
tors leads to an increase in the excitability of neurons
on which they are localized. For example, experi-
ments conducted on the anterodorsal thalamic neu-
rons have demonstrated that 5-HT7 receptors mediate
membrane depolarization via an increase of the
hyperpolarization-activated current I(h) [16, 17].
Similarly, the 5-HT7 receptor-dependent modulation
of I(h) is also one of suggested mechanism of the in-
crease of the excitability in rat dorsal root ganglion
neurons [14]. The stimulatory effect of the activation
of 5-HT7 receptors on synaptic transmission has also
been shown in deep dorsal horn neurons [27]. It has
been speculated that 5-HT7 receptor antagonist-
induced increase in brain serotonin release is due to
a complex GABA-glutamatergic-serotonergic interac-
tion in the DRN [33, 43, 80] and it has been suggested
that 5-HT release may be mediated via blockade of
5-HT7 receptors localized on GABAergic interneu-
rons in the DRN [21]. The studies conducted by Rob-
erts et al. [80] and Glass et al. [29] have suggested
that 5-HT7 receptors in the DRN are localized, among
others, on GABAergic cells. However, mainly due to
the lack of selective agonists, there are no detailed
characteristics of the effects of activation and block-
ade of the 5-HT7 receptor in those brain structures,
which are thought to be most important in the context
of pathophysiology of affective disorders.
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Theeffects of 5-HT7 receptor activation
on hippocampal excitatory and inhibitory
neurons and synaptic connections
In order to get insight into the role played in normal
conditions by the 5-HT7 receptor in excitatory and in-
hibitory neurons of the hippocampus, a brain structure
receiving a massive serotonergic innervation, the ef-
fects of the activation of this receptor were investi-
gated in the CA1 area using whole-cell recording in
rat in vitro brain slices. Due to a lack of a selective
5-HT7 receptor agonist, in order to activate 5-HT7
receptors a wider-spectrum serotonin agonist 5-CT
was applied in the presence of WAY 100635, a selec-
tive 5-HT1A receptor antagonist, the latter being intro-
duced into the slice incubation medium at least 1 h be-
fore 5-CT. The results indicate that the 5-HT7 receptor
increases the excitability of excitatory, pyramidal neu-
rons via a reduction in the amplitude of the slow after-
hyperpolarizing potential (sAHP), an attenuation of
the spike frequency adaptation and 2 to 6 mV depo-
larization [97]. The mechanism of the 5-HT7 receptor-
mediated decrease of sAHP and the reduction of the
spike frequency adaptation has been attributed to the
inhibition of Ca2+-activated K+ channels (KAHP).
Earlier research from this laboratory demonstrated
that these channels play an important role in modula-
tion of excitability of CA1 pyramidal neurons [9]. It
has been shown that numerous types of excitatory re-
ceptors (a.o., 5-HT4, b-adrenergic, muscarinic, hista-
minic, metabotropic glutamate mGluR1) close potas-
sium channels of this type. It appears that these chan-
nels are deactivated via phosphorylation, mainly by
the protein kinase A (PKA), but also by the protein
kinase C (PKC) [9]. The findings reported by other
researchers confirm that 5-HT7 receptors modulate
the excitability of hippocampal pyramidal neurons of
the CA3 area by closing potassium channels of the
KAHP type [5].
The activity of hippocampal excitatory, pyramidal
neurons remains under control of GABAergic feed-
forward or feed-back connections [24, 25]. It has been
suggested that the activation of 5-HT7 receptors
modulates the function of GABAergic interneurons in
the raphe nuclei [80]. The activation of 5-HT7 recep-
tors enhances the excitability of GABAergic neurons
in globus pallidus [18] but 5-HT7 receptors decrease
GABA-dependent currents in the SCN [43]. There-
fore, we examined the effect of the activation of
5-HT7 receptors on GABAergic, spontaneous post-
synaptic inhibitory currents (sIPSCs) recorded from
CA1 pyramidal neurons.
The activation of 5-HT7 receptors increased the
mean sIPSCs frequency while the mean sIPSCs am-
plitude remained unchanged [93]. An increased fre-
quency of spontaneous postsynaptic currents reflects
either the enhanced firing of presynaptic cells, or in-
creased neurotransmitter release and/or changes in the
number of neurotransmitter release sites. Hence, sev-
eral mechanisms may potentially account for the ob-
served 5-HT7 receptor-dependent enhancement of
GABA release. It is conceivable that 5-HT7 receptor
activation directly raises the excitability of interneu-
rons and/or increases the release of GABA via activa-
tion of 5-HT7 receptors located on presynaptic termi-
nals. Alternatively, the enhanced release of GABA
may be an indirect consequence of the increased glu-
tamatergic, excitatory input to GABAergic cells due
to activation of 5-HT7 receptors located in the periso-
matic region of glutamatergic neurons. Immunohisto-
chemical studies have demonstrated the presence of
5-HT7 receptors on the cell bodies of pyramidal neu-
rons in the CA1 area [8]. Indeed, successive experi-
ments indicated an increase in the frequency of
sEPSCs recorded from interneurons after 5-CT appli-
cation [93]. Furthermore, after the blockade of gluta-
matergic transmission by the nonselective antagonist,
kynurenic acid [26, 74], the magnitude of 5-HT7
receptor-induced effect on the frequency of sIPSCs
recorded from pyramidal cells was significantly
weaker [93]. Hence, the above data suggest that
5-HT7 receptor-induced increase in GABA release is
partly due to the increased excitatory input to
GABAergic neurons.
Another mechanism underlying the stimulatory ef-
fect of 5-HT7 receptor activation on sIPSCs frequency
seems to operate through 5-HT7 receptors localized
on GABAergic cells. To the best of our knowledge,
there are no data which would confirm the expression
of these receptors in hippocampal interneurons. How-
ever, several authors have concluded that 5-HT7 re-
ceptors are expressed, for example, in GABAergic
cells in the DRN [20, 21, 29, 80]. The increase in in-
terneuron firing rate cannot account for the observed
effect on sIPSCs frequency, as no 5-CT-induced
changes in GABAergic interneuron excitability have
been reported [93]. Moreover, in the presence of kyn-
urenic acid and, additionally, TTX, the sodium chan-
nel blocker, activation of 5-HT7 receptors still in-
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duced an increase in sIPSCs frequency [93]. Thus, it
seems conceivable that 5-HT7 receptors modulate the
release of GABA from axon terminals. Further studies
using immunochemical methods are necessary to ver-
ify the expression of 5-HT7 receptors on hippocampal
GABAergicinterneurons.
The influence of corticosterone and
antidepressant drugs on the reactivity of
the 5-HT7 receptor in hippocampal neurons
Our earlier experiments have shown that electrocon-
vulsive therapy (ECS) and repeated administration of
antidepressants (imipramine, citalopram) increase the
inhibitory effect of 5-HT in the hippocampus via two
mechanisms: (a) the increased response to the activa-
tion of inhibitory 5-HT1A receptors and (b) the dimin-
ished effect of activation of excitatory 5-HT4 recep-
tors [10, 90]. To study the influence of antidepressant
drugs on the effect of activation of 5-HT7 receptors,
our laboratory used the measurements of spontaneous
epileptiform bursts, recorded from the CA3 hippocam-
pal area under nominally Mg2+-free incubation condi-
tions in rat in vitro brain slices. Activation of 5-HT7 re-
ceptors induced an increase in the frequency of sponta-
neous epileptiform bursts, recorded from the CA3 area
under nominally Mg2+-free incubation conditions, was
increased after 5-CT application [96]. In this experi-
mental model, repeated treatment with the SSRI, cita-
lopram, or the tricyclic antidepressant, imipramine, re-
sulted in attenuation of the excitatory effects of activa-
tion of hippocampal 5-HT7 receptors [96].
The repeated stressors often cause a variety of dis-
turbances and irregularities in the cognitive, emo-
tional and physiological processes of the organism
[58, 107]. A chronic high level of corticosteroid hor-
mones (cortisol in humans and corticosterone in ro-
dents) leads to hyperactivity [77], deregulation of the
functions of the hypothalamus-pituitary-adrenal (HPA)
axis and disrupts the mechanism of the HPA axis
negative feedback [64, 87]. Since a prolonged eleva-
tion of plasma cortisol level often occurs in the course
of depressive disorders in human patients, it has been
commonly accepted that long-lasting alterations in the
activity of the HPA axis are a risk factor to the pre-
cipitation of the disease [71]. Repeated corticosterone
administration has often been used as an animal
model for studying the effects of prolonged stress and
a role of stress in depression [86, 100, 109]. It has
been shown that corticosterone injections repeated for
21 days increased the percentage of immobility time
and decreased the percentage of swimming time in
a forced swim test; those two effects being commonly
regarded as a depression-like behavior in rats [31].
A specific advantage of this model is the elimination
of the adaptation of the organism to a repeated stres-
sor [64, 65, 77]. An earlier study from this laboratory
showed that repeated corticosterone administration
caused changes in the reactivity of 5-HT1A and 5-HT4
receptors in the CA1 area of the hippocampus, which
were reversed by a simultaneous treatment with imi-
pramine [108]. Testing the effects of the activation of
5-HT7 receptors has proven that repeated corticoster-
one administration increased the reactivity of rat CA3
hippocampal circuitry to the activation of this recep-
tor. Moreover, it has been demonstrated that imi-
pramine, administered concurrently with corticoster-
one, counteracted changes occurring due to corticos-
terone. It has also been shown that in rats treated with
corticosterone and imipramine, the functional modifi-
cation in the reactivity of 5-HT7 receptors was not ac-
companied with changes in the binding of the selec-
tive ligand [3H]SB 269970 [95]. These results suggest
that imipramine and corticosterone treatments modify
neither the number of receptors nor their binding
properties but they influence in an opposite manner
the signaling cascades downstream the receptor.
These modifications are likely to involve changes in
the capacity of the receptor to activate G protein
and/or changes in G protein expression or phosphory-
lation [15, 50, 69]. These data are consistent with the
results obtained by other investigators who demon-
strated that multiple ECS, lithium and fluoxetine re-
duced the quantity of mRNA for the a subunit of the
Gs protein in the CA1 hippcampal area [48, 59], while
fluoxetine, imipramine, clomipramine, desimipramine
and clorgyline also reduced the protein amount of the
a subunit of the Gs [50, 49].
The influence of the blockade of the
hippocampal 5-HT7 receptor on its reactivity
Recent research has demonstrated a synergistic inter-
action between compounds acting as 5-HT receptor
antagonists and several antidepressant drugs, including
the specific 5-HT7 receptor antagonist SB 269970.
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Moreover, inactivation and blockade of the 5-HT7
receptor have been shown to induce antidepressant-like
behavioral effects in animal models [32, 35, 101, 102].
Several psychotropic drugs exhibit a high affinity for
5-HT7 receptors [52]. Our earlier study indicated an at-
tenuation of the effects of the activation of 5-HT7 re-
ceptors in rat hippocampus after treatment with the an-
tidepressant drugs, imipramine and citalopram [96].
Collectively, these findings support the hypothesis that
one important mechanism of the therapeutic effects of
chronic treatment with antidepressants may be related
to the blockade of the 5-HT7 receptor.
Since only acute administration of the 5-HT7 recep-
tor antagonist SB 269970 has been investigated be-
fore, we set up to examine and compare the effects of
acute and prolonged treatment with SB 269970 on the
reactivity of the 5-HT7 receptor using a biochemical
and electrophysiological approach. The obtained re-
sults showed that both acute and repeated treatment
with SB 269970 decreased the reactivity of the 5-HT7
receptor assessed with the use of the recording of
spontaneous epileptiform activity in the hippocampal
CA3 area under nominally Mg2+-free incubation con-
ditions [98]. The mechanisms underlying the ob-
served attenuation of the excitatory effect of the
5-HT7 receptor activation by SB 269970 may poten-
tially be related to either the decreased receptor den-
sity or the modification in the capacity of the receptor
to activate G protein, changes in G protein expression
or phosphorylation, or modifications at the level of ef-
fectors. The data demonstrated that both single and
repeated SB 269970 administration lowered the level
of mRNA of those G proteins (Gas and Ga12) which
couple to the 5-HT7 receptor in the hippocampus
[103]. Repeated treatment with SB 269970 also de-
creased the density of 5-HT7 receptors [98]. These ef-
fects differed markedly from the effects of the antide-
pressant imipramine, which altered neither the level
of the mRNAs nor the density of 5-HT7 receptors
when administered once or repeatedly for 14 days.
Also, in contrast to imipramine, repeated SB 269970
administration decreased the mean basal bursting fre-
quency in hippocampal slices. The most likely expla-
nation of this phenomenon is a reduction of excitatory
synaptic transmission due to SB 269970 treatment.
These results indicate that changes induced by the ad-
ministration of SB 269970 depend, at least in part, on
the mechanisms which are different from those under-
lying the effects of the antidepressant drug imi-
pramine.
Besides modulation of membrane excitability, activa-
tion of hippocampal 5-HT7 receptors has been shown to
stimulate neurite outgrowth [47]. Both Gas and Ga12
proteins can regulate cellular morphology by activating
different signaling cascades. Gas protein-mediated mor-
phogenic effects are produced by either modulation of
cAMP concentration [19] or a direct binding of the Gas
protein to the cytoskeleton [106]. Downstream Ga12
protein effectors, which mediate changes in the actin cy-
toskeleton, are members of the Rho family of small
GTPases, including RhoA, Rac1 and Cdc42 [41]. The
major functional effects of this pathway include actin re-
organization and the formation of neurite-like protru-
sions and are mediated by the activation of Cdc42 [47].
It is proposed that the activation of the 5-HT7 receptor
by Gas and Ga12 proteins may stimulate glutamater-
gic synaptic transmission by a positive influence on
a number of functional synapses. Hence, the prolonged
blockade of the 5-HT7 receptor, resulting in a decreased
expression of Gas and Ga12 proteins, might account for
the observed reduction of glutamatergic transmission.
Thus, the experiments showed that the blockade of
the 5-HT7 receptor by SB 269970 led to a functional
desensitization of the 5-HT7 receptor system at the
level of effector proteins, although we note that
changes in the receptor density occurred after chronic
treatment with the antagonist. The phenomenon of
5-HT7 receptor system downregulation may be an im-
portant factor in the mechanism of the antidepressant
effect of the 5-HT7 antagonist, as well as in the modu-
lationof reactivity of other neurotransmitter systems.
The influence of antidepressant drugs
and the blockade of 5-HT7 receptors on
glutamatergic transmission in rat frontal
cortex
Emotional and cognitive processes, which are dis-
rupted in course of affective disorders, depend on the
limbic areas of the brain. The limbic system is con-
nected with the frontal cortex, a part of the cerebral
cortex responsible for the integration of emotional re-
actions with cognitive processes and the control of be-
havior. The abnormalities in cognitive functions and
emotional behavior occurring during depressive dis-
orders implicate the involvement of the frontal cortex
in the pathophysiology of depression and in the action
of antidepressant drugs [44, 45, 55].
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A growing body of evidence indicates that abnor-
malities in the glutamatergic transmission play an im-
portant role in the pathophysiology of mood disor-
ders, and that the common mechanism of antidepres-
sant therapies involves modifications in the function
of the glutamatergic system [46, 70, 72]. The unmet
need for an improved pharmacotherapy of treatment-
resistant depression has resulted in a search for new
compounds with new mechanisms of action such as
those expressing affinity for glutamate receptors [7,
42, 54, 70]. It has been shown that N-methyl-D-
aspartate (NMDA) receptor antagonists exhibit anti-
depressant-like actions in animal behavioral models
and potentiate the effects of antidepressants [99]. It
has also been established that chronic treatment with
various antidepressants results in a reduction of the
radioligand binding to rat cortical NMDA receptors
[66, 67]. On the basis of these findings it has been hy-
pothesized that the mechanism of antidepressant action
is related to the attenuated function of NMDA recep-
tors in the cerebral cortex [75, 83]. According to the
glutamate hypothesis of depression, the glutamatergic
system is a primary mediator of psychiatric pathology
and, potentially, also a final common pathway for the
therapeutic action of antidepressants [3, 39, 46].
Despite a substantial body of evidence indicating
the involvement of adaptive changes in the function
of NMDA receptors during antidepressant therapies,
no attempts have yet been made to assess changes in
cortical glutamatergic receptor functions using an
electrophysiological approach. Therefore, we aimed
at finding effects of repeated administration of the tri-
cyclic antidepressant, imipramine, on glutamatergic
transmission in rat frontal cortex using whole-cell re-
cording. Since our previous study showed that sero-
tonin, acting via 5-HT7 receptors, exerted significant
modulatory influence on synaptic transmission in rat
hippocampus, it was conceivable that the antidepres-
sant-like effects of the 5-HT7 receptor antagonist may
be related to its modulatory action on glutamatergic
transmission also in the cortex. Therefore, we also in-
vestigated the effects of single and repeated admini-
stration of the 5-HT7 antagonist SB 269970 on gluta-
matergic neurons and excitatory synaptic transmis-
sion in slices of the rat cortex. Our study showed that
repeated administration of imipramine and SB 269970
strongly reduced the mean frequency and, to a smaller
extent, the mean amplitude of sEPSCs recorded from
layer II/III cortical pyramidal neurons 2 days after ter-
minationof the treatment [94, 92].
Frontal cortex receives a dense serotonergic input
from the DRN [68]. Being released from axon termi-
nals of the raphe neurons, serotonin has been shown
to affect the action of several neurotransmitters by the
heterosynaptic activation of 5-HT receptors located
on neighboring axon terminals [23]. The heterosynap-
tic activation of 5-HT receptors on glutamatergic neu-
rons has been shown to inhibit or stimulate glutamate
release in the cortex via 5-HT1A, 5-HT1B or 5-HT2A
receptors, respectively [13, 30, 57]. Hence it is con-
ceivable that the decrease in glutamatergic transmis-
sion after repeated imipramine or chronic blockade of
5-HT7 receptors, observed in our study, occurs as a re-
sult of the activation of other classes of 5-HT receptors,
but not 5-HT7 receptors, by a prolonged elevation of
the 5-HT level in the cortex induced by the blockade of
5-HT7 receptors in the DRN. So far, only a few studies
have examined the effect of SB-269970, administered
alone or jointly with antidepressant drugs, on 5-HT re-
lease in the cortex. Weso³owska and Kowalska [101]
demonstrated that both SB-269970 and imipramine in-
creased the efflux of DA, NA and 5-HT in rat prefron-
tal cortex. On the other hand, some authors found that
SB-269970 significantly inhibited 5-HT efflux [79].
It is well known that the functional changes that
occur within the presynaptic terminals affect the fre-
quency of sEPSCs, while the amplitude of postsynap-
tic currents depends on both presynaptic factors, such
as the amount of neurotransmitters in synaptic vesi-
cles, and postsynaptic ones – mainly the number of
receptors for the neurotransmitter e.g., [78]. It is con-
ceivable that the observed decrease in the frequency
of sEPSCs may potentially result from the imi-
pramine- or SB 269970-induced decrease in the spon-
taneous firing of cells synapsing on neurons from
which the recording was made. However, all recorded
cells showed no spontaneous spiking during the initial
current-clamp recording at the resting membrane po-
tential. Moreover, the lack of a significant change in
the mean frequency of sEPSC after the blockade of
Na channels in the tested sample of neurons suggested
that a majority of recorded sEPSCs corresponded to
miniature EPSCs whose frequency is not related to
the spiking activity of presynaptic cell. Hence, an ap-
proximately two-fold decrease in the sEPSC mean
frequency, observed in the present study, resulted
from the diminution of glutamate release [51].
The observed reduction in the mean amplitude of
sEPSCs may principally result from changes in the
membrane resistance, however, neither imipramine
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nor SB 269970 affected the basic electrophysiological
parameters of the recorded neurons (input resistance,
resting membrane potential and excitability). The
comparison between the NMDA and the AMPA/kai-
nate receptor-mediated electrically evoked EPSCs
ratio indicated that, at least in the case of imipramine,
chronic treatment led to a relative reduction of the
NMDA receptor-mediated response and/or decrease
inits density [92].
The effects of repeated stress and the
5-HT7 receptor antagonist on long-term
potentiation in rat frontal cortex
Memory disturbances belong to the most common
symptoms of depression and other illnesses caused by
repeated stress or traumatic experiences. For example,
repeated restraint stress has been shown to induce
a strong desensitization of the hypothalamic-pituitary-
adrenal axis and an elevation of plasma corticosterone
level e.g., [28]. Long-term potentiation (LTP) of syn-
aptic transmission is an experimental model of cellu-
lar and molecular changes that seem to underlie the
formation and maintenance of memory traces in the
brain. The processes involved in the induction and
maintenance of LTP are still not fully understood, but
an external manifestation of this phenomenon, i.e., the
activity-dependent increase in the efficiency of synap-
tic connections lasting for several weeks, is an exam-
ple of the strengthening of synaptic connection, de-
pending on simultaneous pre-and postsynaptic activ-
ity. LTP has been shown to be suppressed by repeated
stress [2, 73]. It has been well documented that, in
general, chronic stress disrupts neural plasticity, while
antidepressant drugs produce an opposite effect [76].
We investigated the effect of repeated restraint
stress on glutamatergic field potentials and LTP in rat
frontal cortex. The animals were subjected to restraint
lasting 10 min twice daily for 3 days. The 5-HT7 re-
ceptor antagonist SB 269970 was administered before
each restraint stress session and would prevent the oc-
currence of changes induced by repeated exposure to
stress. The obtained data indicate that the 5-HT7 re-
ceptor antagonist SB 269970 prevents the occurrence
of the restraint stress-induced enhancement of gluta-
matergic transmission and attenuation of LTP in rat
frontal cortex [91]. We also demonstrated that re-
peated corticosterone treatment enhances excitatory
synaptic transmission and impairs LTP in rat frontal
cortex, whereas the tricyclic antidepressant imi-
pramine, administered jointly with corticosterone,
normalizes the enhanced basal excitatory synaptic
transmission and the reduced potential for long-term
synaptic plasticity, evoked by repeated corticosterone
administration [11]. Intraperitoneal administration of
SB-269970 raises the extracellular levels of serotonin
as well as these of dopamine, noradrenaline in rat pre-
frontal cortex, thus resembling the effect of admini-
stration of antidepressant drugs [12, 33, 101]. It may
be hypothesized that the elevated level of 5-HT and/or
noradrenaline compensates the effect of restraint
stress on glutamatergic transmission and synaptic
plasticity.
Conclusions
The data obtained in the course of studies summarized
here indicate that serotonin, by acting through 5-HT7
receptors, exerts modulatory influence on hippocam-
pal excitatory cells and on glutamate and GABA me-
diated synaptic transmission in rat hippocampus.
Since the prolonged blockade of 5-HT7 receptors de-
creases glutamatergic transmission in the frontal cor-
tex in a similar way as does imipramine, and it re-
stores the capacity of cortical excitatory synapses to
undergo antagonists of the 5-HT7 receptor as new
substances to be possibly applied in the treatment of
affective disorders. Identification of this novel 5-HT7
receptor-mediated effect seems important to the eluci-
dation of the physiological significance of these re-
ceptors. These studies provide new information about
the involvement of 5-HT7 receptors in the mecha-
nisms which allow serotonin to simultaneously re-
model neuronal activity in a functionally appropriate
manner in a wide variety of cell types and excitatory
and inhibitory circuits in the hippocampus.
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